Agreed. There is already a huge spec premium built into the price of this stock, it could be a 20 cent stock without that. The almost daily griping about price action and "shorts" here is indicative of people who confuse investing with cheerleading, high school drama class, or an episode of "The X Files". Outside of algo trading penny flippers, no should care about daily ups and downs of a few cents in the price.
However, the company getting JW and PP and their amateur hucksterism off to the side, and someone with industry experience and connections in place is good news in the long run. Question is, with income appearing to have flatlined and needing more capital to pursue FDA approval, how much dilution do we face?
The potential good news on the horizon now would be that bigger players might, at some point after Mullan establishes his plans, see this is a spec biotech opportunity, and build an even bigger premium into the stock than the one we have now.
Unlike the present time where results of tests are met with collective yawns, positive results from testing along an FDA approval track could potentially trigger the price shocks that people here repeatedly, mistakenly think are coming for an otc dietary supplement that sits on a store shelf already, next to the protein powder and valerian root. But all of that depends on many variables and the downside risk is real. A "buzz" about Star having a potential alzheimer's drug would probably yield the biggest potential boost you could hope for down the line.
This stock is still a huge gamble and your point that people here constantly confuse their dreams of avarice with reality is well taken.
